Maxim Group Reiterates $5 Price Target on Mast Therapeutics (MSTX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Mast Therapeutics (MSTX) Offers Business Update; Phase 3 EPIC Enrollment Surpasses 90% Mark
January 7, 2016 8:06 AM ESTMast Therapeutics, Inc. (NYSE: MSTX) provided a business update.
The Company reported that patient enrollment in the pivotal Phase 3 "EPIC" study of its lead product candidate, vepoloxamer (MST-188), in sickle cell disease recently surpassed the 90% mark. The Company expects to complete patient enrollment in February. Consistent with prior guidance, the Company expects to report top-line results in the second quarter of... More